IDEAYA Biosciences, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| IDEAYA Biosciences, Inc. | IDYA - NASDAQ |
$13.00-$15.00 | $10.00 | $14.00 | 5 million | 5/23/2019 |
| JP Morgan, Citigroup, Jefferies | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-04-26 Terms Added 2019-05-13 | ||||||
IDEAYA Biosciences, Inc. Quote & Chart - Click for current quote - IDYA
IPO Boutique aggregates information on public companies and private companies, such as "IDYA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About IDEAYA Biosciences, Inc. (adapted from IDEAYA Biosciences, Inc. prospectus):
They are an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "IDYA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.